Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Published:2016-08 Issue:8 Volume:17 Page:1114-1126
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Boer Stephanie M,Powell Melanie E,Mileshkin Linda,Katsaros Dionyssios,Bessette Paul,Haie-Meder Christine,Ottevanger Petronella B,Ledermann Jonathan A,Khaw Pearly,Colombo Alessandro,Fyles Anthony,Baron Marie-Helene,Kitchener Henry C,Nijman Hans W,Kruitwagen Roy F,Nout Remi A,Verhoeven-Adema Karen W,Smit Vincent T,Putter Hein,Creutzberg Carien L

Funder

Dutch Cancer Society, Netherlands

National Health and Medical Research Council

Italian Medicines Agency

Canadian Cancer Society Research Institute

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up;Colombo;Ann Oncol,2016

2. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis;Blake;Lancet,2009